본문 바로가기
KERD
논문KCI 등재

Dendritic Cell Dysfunction in Patients with End-stage Renal Disease

김시내|김미연|이시영|김수현|김현우|김은혜|김지웅|Tam Thanh Nguyen
대한면역학회 (The Korean Association of Immunologists)|2017.06|Immune Network|제17권 제3호|pp. 152-162|DOI https://doi.org/10.4110/in.2017.17.3.152

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

Dendritic cellsEnd-stage renal diseaseImmunodeficiencyCostimulatory moleculeAntigen presenting cells

초록

End-stage renal disease (ESRD) with immune disorder involves complex interactions between the innate and adaptive immune responses. ESRD is associated with various alterations in immune function such as a reduction in polymorphonuclear leukocyte bactericidal activity, a suppression of lymphocyte proliferative response to stimuli, and a malfunction of cell-mediated immunity at the molecular level. ESRD also increases patients’ propensity for infections and malignancies as well as causing a diminished response to vaccination. Several factors influence the immunodeficiency in patients with ESRD, including uremic toxins, malnutrition, chronic inflammation, and the therapeutic dialysis modality. The alteration of T-cell function in ESRD has been considered to be a major factor underlying the impaired adaptive cellular immunity in these patients. However, cumulative evidence has suggested that the immune defect in ESRD can be caused by an Ag-presenting dendritic cell (DC) dysfunction in addition to a T-cell defect. It has been reported that ESRD has a deleterious effect on DCs both in terms of their number and function, although the precise mechanism by which DC function becomes altered in these patients is unclear. In this review, we discuss the effects of ESRD on the number and function of DCs and propose a possible molecular mechanism for DC dysfunction. We also address therapeutic approaches to improve immune function by optimally activating DCs in patients with ESRD.

Abstract

End-stage renal disease (ESRD) with immune disorder involves complex interactions between the innate and adaptive immune responses. ESRD is associated with various alterations in immune function such as a reduction in polymorphonuclear leukocyte bactericidal activity, a suppression of lymphocyte proliferative response to stimuli, and a malfunction of cell-mediated immunity at the molecular level. ESRD also increases patients’ propensity for infections and malignancies as well as causing a diminished response to vaccination. Several factors influence the immunodeficiency in patients with ESRD, including uremic toxins, malnutrition, chronic inflammation, and the therapeutic dialysis modality. The alteration of T-cell function in ESRD has been considered to be a major factor underlying the impaired adaptive cellular immunity in these patients. However, cumulative evidence has suggested that the immune defect in ESRD can be caused by an Ag-presenting dendritic cell (DC) dysfunction in addition to a T-cell defect. It has been reported that ESRD has a deleterious effect on DCs both in terms of their number and function, although the precise mechanism by which DC function becomes altered in these patients is unclear. In this review, we discuss the effects of ESRD on the number and function of DCs and propose a possible molecular mechanism for DC dysfunction. We also address therapeutic approaches to improve immune function by optimally activating DCs in patients with ESRD.

참고문헌 (90)

  1. Webster, A. C., "Chronic Kidney Disease", Lancet, 389, pp.1238~1252 (2017)
  2. Anding, K., "The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing", Nephrol. Dial. Transplant, 18, pp.2067~2073 (2003)
  3. Verkade, M. A., "Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients", Kidney Int, 66, pp.614~621 (2004)
  4. Sester, M., "Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients", Kidney Int, 65, pp.1826~1834 (2004)
  5. Yoon, J. W., "Naïve and central memory T-cell lymphopenia in end-stage renal disease", Kidney Int, 70, pp.371~376 (2006)
  6. Lim, W. H., "Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients", Kidney Int, 72, pp.1138~1148 (2007)
  7. Litjens, N. H., "Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients", J. Am. Soc. Nephrol, 19, pp.1483~1490 (2008)
  8. Hauser, A. B., "Characteristics and causes of immune dysfunction related to uremia and dialysis", Perit. Dial. Int. Suppl, 3(Suppl), pp.S183~S187 (2008)
  9. Kato, S., "Aspects of immune dysfunction in end-stage renal disease", Clin. J. Am. Soc. Nephrol, 3, pp.1526~1533 (2008)
  10. Cohen, G., "Immune dysfunction in uremia—an update", Toxins (Basel), 4, pp.962~990 (2012)
  11. Girndt, M., "Molecular aspects of T- and B-cell function in uremia", Kidney Int. Suppl, 78, pp.S206~S211 (2001)
  12. Girndt, M., "T cell activation defect in hemodialysis patients: evidence for a role of the B7", CD28 pathway, 1993, pp.44, 359~365
  13. Verkade, M. A., "Functional impairment of monocyte-derived dendritic cells in patients with severe chronic kidney disease", Nephrol. Dial. Transplant, 22, pp.128~138 (2007)
  14. Betjes, M. G., "Seropositivity for cytomegalovirus in patients with end-stage renal disease is strongly associated with atherosclerotic disease", Nephrol. Dial. Transplant, 22, pp.3298~3303 (2007)
  15. Hubo, M., "Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells", Front. Immunol, 4, pp.82~ (2013)
  16. Ganguly, D., "The role of dendritic cells in autoimmunity", Nat. Rev. Immunol, 13, pp.566~577 (2013)
  17. Hesselink, D. A., "The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells", Nephrol. Dial. Tranplant, 20, pp.1868~1873 (2005)
  18. Lim, W. H., "Renal transplantation reverses functional deficiencies in circulating dendritic cell subsets in chronic renal failure patients", Transplantation, 81, pp.160~168 (2006)
  19. Verkade, M. A., "Decreased antigen-specific T-cell proliferation by moDC among hepatitis B vaccine nonresponders on haemodialysis", Clin. Exp. Med, 7, pp.65~71 (2007)
  20. Lim, W. H., "Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients", Kidney Int, 72, pp.1138~1148 (2007)
  21. Robinson, S. P., "Human peripheral blood contains two distinct lineages of dendritic cells", Eur. J. Immunol, 29, pp.2769~2778 (1999)
  22. Ardavín, C., "Origin and differentiation of dendritic cells", Trends Immunol, 22, pp.691~700 (2001)
  23. Chowdhury, F., "Enumeration and phenotypic assessment of human plasmacytoid and myeloid dendritic cells in whole blood", Cytometry A, 77, pp.328~337 (2010)
  24. Jarrossay, D., "Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells", Eur. J. Immunol, 31, pp.3388~3393 (2001)
  25. Agrawal, S., "Effects of end-stage renal disease and haemodialysis on dendritic cell subsets and basal and LPS-stimulated cytokine production", Nephrol. Dial. Transplant, 25, pp.737~746 (2010)
  26. Paul, K., "Circulating dendritic cell precursors in chronic kidney disease: a cross-sectional study", BMC Nephrol, 10(14), pp.274~ (2013)
  27. Merad, M., "Dendritic cell homeostasis", Blood, 113, pp.3418~3427 (2009)
  28. Yilmaz, A., "Decrease in circulating myeloid dendritic cell precursors in coronary artery disease", J. Am. Coll. Cardiol, 48, pp.70~80 (2006)
  29. Yilmaz, A., "Predictive value of the decrease in circulating dendritic cell precursors in stable coronary artery disease", Clin. Sci. (Lond), 116, pp.353~363 (2009)
  30. Kretzschmar, D., "Recruitment of circulating dendritic cell precursors into the infarcted myocardium and pro-inflammatory response in acute myocardial infarction", Clin. Sci. (Lond), 123, pp.387~398 (2012)
  31. Wen, J., "A decrease in the percentage of circulating mDC precursors in patients with coronary heart disease: a relation to the severity and extent of coronary artery lesions?", Heart Vessels, 28, pp.135~142 (2013)
  32. Chen, L., "Molecular mechanisms of T cell co-stimulation and co-inhibition", Nat. Rev. Immunol, 13, pp.227~242 (2013)
  33. Harding, F. A., "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones", Nature, 356, pp.607~609 (1992)
  34. Choi, H. M., "Altered monocyte-derived dendritic cell function in patients on hemodialysis: a culprit for underlying impaired immune responses", Clin. Exp. Nephrol, 15, pp.546~553 (2011)
  35. Cao, Q., "Macrophages and dendritic cells for treating kidney disease", Nephron. Exp. Nephrol, 117, pp.e47~e52 (2011)
  36. Lim, W. H., "Uremia impairs blood dendritic cell function in hemodialysis patients", Kidney Int, 71, pp.1122~1131 (2007)
  37. Gluba, A., "The role of Toll-like receptors in renal diseases", Nat. Rev. Nephrol, 6, pp.224~235 (2010)
  38. Koc, M., "Toll-like receptor expression in monocytes in patients with chronic kidney disease and haemodialysis:relation with inflammation", Nephrol. Dial. Transplant, 26, pp.955~963 (2011)
  39. Ando, M., "Reduced expression of Toll-like receptor 4 contributes to impaired cytokine response of monocytes in uremic patients", Kidney Int, 70, pp.358~362 (2006)
  40. Kuroki, Y., "A study of innate immunity in patients with end-stage renal disease: special reference to toll-like receptor-2 and -4 expression in peripheral blood monocytes of hemodialysis patients", Int. J. Mol. Med, 19, pp.783~790 (2007)
  41. Gollapudi, P., "Leukocyte toll-like receptor expression in endstage kidney disease", Am. J. Nephrol, 31, pp.247~254 (2010)
  42. Geara, A. S., "Effects of parathyroid hormone on immune function", Clin. Dev. Immunol, pii, pp.418695~ (2010)
  43. Guy, B., "The perfect mix: recent progress in adjuvant research", Nat. Rev. Microbiol, 5, pp.505~517 (2007)
  44. Girndt, M., "Prospective crossover trial of the influence of vitamin E-coated dialyzer membranes on T-cell activation and cytokine induction", Am. J. Kidney. Dis, 35, pp.95~104 (2000)
  45. Contin-Bordes, C., "Potential role of the soluble form of CD40 in deficient immunological function of dialysis patients: new findings of its amelioration using polymethylmethacrylate (PMMA) membrane", NDT. Plus, 3(Suppl 1), pp.i20~i27 (2010)
  46. Martínez-Miguel, P., "Evaluation of a polynephron dialysis membrane considering new aspects of biocompatibility", Int. J. Artif. Organs, 38, pp.45~53 (2015)
  47. Rama, I., "Online haemodiafiltration improves inflammatory state in dialysis patients: A longitudinal study", PLoS One, 11, pp.e0164969~ (2016)
  48. Ward, R. A., "A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study", J. Am. Soc. Nephrol, 11, pp.2344~2350 (2000)
  49. Karkar, A., "A randomized trial on health-related patient satisfaction level with highefficiency online hemodiafiltration versus high-flux dialysis", Blood Purif, 40, pp.84~91 (2015)
  50. Dede, F., "Modulation of the immune response to HBV vaccination by hemodialysis membranes", Int. Urol. Nephrol, 42, pp.1069~1075 (2010)
  51. Sasaki, R., "Pleiotropic functions of erythropoietin", Intern. Med, 42, pp.142~149 (2003)
  52. Arcasoy, M. O., "The non-haematopoietic biological effects of erythropoietin", Br. J. Haematol, 141, pp.14~31 (2008)
  53. Nairz, M., "The pleiotropic effects of erythropoietin in infection and inflammation", Microbes Infect, 14, pp.238~246 (2012)
  54. Rocchetta, F., "Erythropoietin enhances immunostimulatory properties of immature dendritic cells", Clin. Exp. Immunol, 165, pp.202~210 (2011)
  55. Kazmi, W. H., "Anemia: an early complication of chronic renal insufficiency", Am. J. Kidney. Dis, 38, pp.803~812 (2001)
  56. Prutchi Sagiv, S., "Erythropoietin effects on dendritic cells: potential mediators in its function as an immunomodulator?", Exp. Hematol, 36, pp.1682~1690 (2008)
  57. Lifshitz, L., "Non-erythroid activities of erythropoietin: Functional effects on murine dendritic cells", Mol. Immunol, 46, pp.713~721 (2009)
  58. Cravedi, P., "Immunosuppressive effects of erythropoietin on human alloreactive T cells", J. Am. Soc. Nephrol, 25, pp.2003~2015 (2014)
  59. Sennesael, J., "Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients", Kidney Int, 40, pp.121~128 (1991)
  60. Anandh, U., "A randomised controlled trial of intradermal hepatitis B vaccination and augmentation of response with erythropoietin", J. Assoc. Physicians India, 48, pp.1061~1063 (2000)
  61. Hassan, K., "The effect of erythropoietin therapy and hemoglobin levels on the immune response to Engerix-B vaccination in chronic kidney disease", Ren. Fail, 25, pp.471~478 (2003)
  62. Katz, O., "Erythropoietin enhances immune responses in mice", Eur. J. Immunol, 37, pp.1584~1593 (2007)
  63. Oster, H. S., "Erythropoietin treatment is associated with an augmented immune response to the influenza vaccine in hematologic patients", Exp. Hematol, 41, pp.167~171 (2013)
  64. Fabrizi, F., "Erythropoietin use and immunogenicity of hepatitis B virus vaccine in chronic kidney disease patients: A meta-analysis", Kidney Blood Press Res, 35, pp.504~510 (2012)
  65. Kausz, A., "The value of vaccination in chronic kidney disease", Semin. Dial, 17, pp.9~11 (2004)
  66. Stevens, C. E., "Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy", N. Engl. J. Med, 311, pp.496~501 (1984)
  67. Peces, R., "Persistence of immunologic memory in long-term hemodialysis patients and healthcare workers given hepatitis B vaccine : role of a booster dose on antibody response", Nephron, 89, pp.172~176 (2001)
  68. Hornell, T. M., "Regulation of the class II MHC pathway in primary human monocytes by granulocyte-macrophage colony-stimulating factor", J. Immunol, 171, pp.2374~2383 (2003)
  69. Storozynsky, E., "Interleukin-3 and granulocyte-macrophage colony-stimulating factor enhance the generation and function of dendritic cells", Immunology, 97, pp.138~149 (1999)
  70. Hanada, K., "GM-CSFinduced in vivo expansion of splenic dendritic cells and their strong costimulation activity", J. Leukoc. Biol, 60, pp.181~190 (1996)
  71. Kapoor, D., "Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients", J. Viral. Hepat, 6, pp.405~409 (1999)
  72. Fabrizi, F., "Metaanalysis:the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease", Aliment. Pharmacol. Ther, 24, pp.789~796 (2006)
  73. Cruciani, M., "Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination : a metaanalysis", Vaccine, 25, pp.709~718 (2007)
  74. Alavian, S. M., "Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials", Clin. Ther, 32, pp.1~10 (2010)
  75. Fabrizi, F., "Meta-analysis:levamisole improves the immune response to hepatitis B vaccine in dialysis patients", Aliment. Pharmacol. Ther, 32, pp.756~762 (2010)
  76. Chen, L. Y., "Levamisole enhances immune response by affecting the activation and maturation of human monocyte-derived dendritic cells", Clin. Exp. Immunol, 151, pp.174~1781 (2008)
  77. Niu X., "Synergistic and additive effects of cimetidine and levamisole on cellular immune responses to hepatitis B virus DNA vaccine in mice", Scand. J. Immunol, 77, pp.84~91 (2013)
  78. Deniz Ayli, M., "Effect of oral levamisole supplementation to hepatitis B vaccination on the rate of immune response in chronic hemodialysis patients", Nephron, 84, pp.291~292 (2000)
  79. Kayataş, M., "Levamisole treatment enhances protective antibody response to hepatitis B vaccination in hemodialysis patients", Artif. Organs, 26, pp.492~496 (2002)
  80. Argani, H., "Levamizole enhances immune responsiveness to intra-dermal and intra-muscular hepatitis B vaccination in chronic hemodialysis patients", J. Immune. Based. Ther. Vaccines, 4, pp.3~ (2006)
  81. Fallahzadeh, M. K., "Effect of levamisole supplementation on tetanus vaccination response rates in haemodialysis patients: a randomized double-blind placebo-controlled trial", Nephrology (Carlton), 19, pp.27~31 (2014)
  82. Sali, S., "Effect of levamisole supplementation on hepatitis B virus vaccination response in hemodialysis patients", Nephrology (Carlton), 13, pp.376~379 (2008)
  83. Sanadgol, H., "Effect of adding levamisole on seroconversion response to hepatitis B virus vaccination in hemodialysis patients: a single-center experience", Iran J. Kidney Dis, 5, pp.338~341 (2011)
  84. Garçon, N., "Glaxo-SmithKline adjuvant systems in vaccines: concepts, achievements and perspectives", Expert Rev. Vaccines, 6, pp.723~739 (2007)
  85. Ulrich, J. T., "Monophosphoryl lipid A as an adjuvant. Past experiences and new directions", Pharm. Biotechnol, 6, pp.495~524 (1995)
  86. Evans, J. T., "Enhancement of antigenspecific immunity via the TLR4 ligands MPL adjuvant and Ribi.529", Expert Rev. Vaccines, 2, pp.219~229 (2003)
  87. Eleftheriadis, T., "Toll-like receptors and their role in renal pathologies", Inflamm. Allergy Drug Targets, 11, pp.464~477 (2012)
  88. Tong, N. K., "Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients", Kidney Int, 68, pp.2298~2303 (2005)
  89. Kong, N. C., "new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients", Kidney Int, 73, pp.856~862 (2008)
  90. Surquin, M., "Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine", Kidney Int, 77, pp.247~255 (2010)

관련 논문AI추천

Effect of Lymphocyte Phenotypic Alterations on the Humoral Response to Vaccination Against SARS-COV-2 in Dialysis PatientsAsouchidou Despina, Christodoulou Michalis, Fylaktou Asimina, Giamalis Panagiotis, Lioulios Georgios, Nikolaidou Vasiliki, Papagianni Aikaterini, Stai Stamatia, Stangou Maria, Tsouchnikas Ioannis, Xochelli Aliki대한진단검사의학회 · Annals of Laboratory Medicine2023 · 제43권 제5호Generation of Tolerogenic Dendritic Cells and Their Therapeutic Applications유승보, 하상준대한면역학회 · Immune Network2016 · 제16권 제1호Prognostic role of the neutrophil-to-lymphocyte ratio in patients with chronic kidney diseaseChang Seong Kim, Eun Hui Bae, Hong Sang Choi, Jin Kim, Sang Heon Suh, Seong Kwon Ma, Soo Wan Kim, Su Hyun Song, Tae Ryom Oh대한내과학회 · The Korean Journal of Internal Medicine2023 · 제38권 제5호Regulation of Intestinal Immune System by Dendritic Cells고현정, 장선영대한면역학회 · Immune Network2015 · 제15권 제1호Tumor necrosis factor α is a risk factor for infection in peritoneal dialysis patientsEunjung Kang, Gyu-Tae Shin, Heungsoo Kim, Hwa Jung Lee, Inhwee Park, Seihran Kim대한내과학회 · The Korean Journal of Internal Medicine2016 · 제31권 제4호Role of T cells in ischemic acute kidney injury and repair이경호, Hye Ryoun Jang대한내과학회 · The Korean Journal of Internal Medicine2022 · 제37권 제3호

이 간행물의 다른 논문 (7건)

The Role of Lipids in Development of Allergic ResponsesManuel Gómez del Moral, Eduardo Martínez-Navespp. 133-143TLR/MyD88-mediated Innate Immunity in Intestinal Graft-versus-Host Disease이영관, 강명수, 최은영pp. 144-151Clonal Expansion of Allergen-specific CD4+ T Cell in the Lung in the Absence of Lymph Nodes김병석, 박영준, 심인보, 정연석, 최가람pp. 163-170Effects of Cellular 11b-hydroxysteroid Dehydrogenase 1 on LPS-induced Inflammatory Responses in Synovial Cell Line, SW982심정현, 김기남, 조영식pp. 171-178Diclofenac Inhibits 27-hydroxycholesterol-induced Differentiation of Monocytic Cells into Mature Dendritic Cells손용해, 김보영, 박영철, 김관회pp. 179-185
원문 보기